The Novusyn Research glossary defines the peptide-chemistry, clinical-trial, regulatory, and analytical-methodology terms used across the desk. Entries cover everything from acetate counterion content and HPLC purity, through trial design language (placebo-controlled, double-blind, non-inferiority, hazard ratio, MACE-3, eGFR slope), to regulatory acronyms (FDA, EMA, MHRA, TGA, ICH, USP, 503A, 503B, RLD, NDA, BLA, ANDA, 505(b)(2)).
Each definition is short, plain-language, and links out to the originating regulator, standards body, or primary literature where appropriate. The glossary is a reading aid for our news, trials, and regulation coverage and is not a substitute for the relevant standard or guideline.